Investors are aggressively rewarding precision genetic interventions and walking away from broad regenerative modulators. The five-companies-burned list above is the most recent precedent set.
Pricing benchmark. Lilly/Seamless $1.12B for a gene-editing platform with no clinical readout sets the deal-size ceiling for “precision otology.” A first-in-class fold-rescue platform with H01 as POC + four follow-on assets (TECTA, CDH23, MYO7A, OTOA) is in the same conceptual reward bracket.
Series A target. Sensorion + Cilcare both raised €40–60M in 2024–2026 with Phase 2a data. An H01 Series A targeting that range is reasonable on a Phase 0/in-vitro fold-rescue confirmation + AAV-incompatibility argument.
Strategic acquirer landscape. Regeneron (acquired Decibel 2023, just got Otarmeni approval), Eli Lilly (acquired Akouos, just inked Seamless), Sanofi (anchored on Sensorion gene-therapy program). All three demonstrated 2024–2026 willingness to acquire/partner otology genetic assets.
Window. The Otarmeni approval (Apr 2026) creates regulatory tailwind — FDA has now approved the first inner-ear genetic therapy. Subsequent precision genetic assets benefit from the de-risked regulatory path.